DRPLA (ATN1) GENE ANALYSIS, EDTA BLOOD

DRPLA stands for Dentatorubral-Pallidoluysian Atrophy, a rare inherited neurodegenerative disorder caused by expansions in the ATN1 gene. The DRPLA gene analysis detects abnormal trinucleotide repeat expansions in this gene that are responsible for the disease. It is commonly diagnosed in individuals who present with symptoms like ataxia, myoclonus, seizures, or cognitive decline.

This analysis is critical for patients with unexplained movement disorders or seizures, particularly when there is a family history of similar conditions. DRPLA has a variable onset and may mimic other neurological disorders, making molecular diagnosis essential for confirmation, prognosis, and family planning decisions.

It is typically recommended for individuals with signs of progressive cerebellar ataxia, myoclonic epilepsy, and dementia, particularly if other causes have been excluded. It may also be performed as part of a differential diagnosis for hereditary ataxias or movement disorders.

A positive test indicates the presence of an expanded CAG repeat in the ATN1 gene, confirming DRPLA. The number of repeats can also offer insight into the age of onset and disease severity. A normal or non-expanded repeat count rules out this particular condition but may not exclude other neurodegenerative diseases.

The test is conducted using DNA extracted from blood or saliva. PCR amplification and fragment analysis or Southern blotting are commonly used to assess the size of the CAG repeat in the ATN1 gene.